medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2020, Número S1

<< Anterior Siguiente >>

Ginecol Obstet Mex 2020; 88 (S1)


Opciones anticonceptivas para las adolescentes

Lira-Plascencia J, Ibargüengoitia-Ochoa F, Neyro JL

Idioma: Español
Referencias bibliográficas: 75
Paginas: 74-87
Archivo PDF: 268.30 Kb.


RESUMEN

De forma global los datos muestran que la mayoría de las mujeres en etapa reproductiva, incluidas las adolescentes, desean métodos modernos de planificación familiar. Muchas de estas mujeres no tienen acceso a la anticoncepción por diferentes causas, lo que se ve reflejado en tasas de fertilidad altas. Puesto que el embarazo durante la adolescencia se considera un problema de salud pública, diferentes instancias han manifestado su interés en establecer directrices específicas para este grupo etario. Esta revisión abarca todos los métodos anticonceptivos, incluida la anticoncepción reversible de larga duración, en particular idónea para las adolescentes. Es importante señalar que prácticamente no existen contraindicaciones para su implementación en este grupo etario.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Piccinino LJ, et al. Trends in contraceptive use in the United States: 1982-1995. Fam Plann Perspect 1998;30(1):1-10, 46. https://www.jstor.org/stable/2991517

  2. INEGI. Encuesta Nacional de la Dinámica Demográfica 2009. Base de datos. http://internet.contenidos.inegi. org.mx/contenidos/Productos/prod_serv/contenidos/ espanol/bvinegi/productos/encuestas/hogares/enadid/ enadid2009/702825495602.pdf

  3. INEGI. Encuesta Nacional de la Dinámica Demográfica 2014. Base de datos. https://www.inegi.org.mx/programas/ enadid/2014/default.html

  4. Norma Oficial Mexicana NOM-047-SSA2-2015. Para la atención a la salud del grupo etario de 10 a 19 años. http://evaluacion.ssm.gob.mx/pdf/normateca/NOM-047- SSA2-2015.pdf

  5. Curtis KM, et al. US medical elegibility criteria for contraceptive use, 2016. MMWR Recomm Rep 2016;65:1-103. https://www.cdc.gov/mmwr/volumes/65/rr/rr6503a1.htm

  6. American College Obstetrician and Gynecologists. Adolescence pregnancy contraception and sexual activity. ACOG Committee Opinion No. 699. Obstet Gynecol 2017;129:965- 966. https://doi.org/10.1097/AOG.0000000000002041.

  7. Trussell J. Contraceptive efficacy. Contraceptive 2011;83(5):397-404. https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC3638209/

  8. GRADE Working Group. http: www.gradeworkinggroup.org

  9. World Health Organization. Medical eligibility criteria for contraceptive use. https://www.who.int/reproductivehealth/ publications/family_planning/Ex-Summ-MEC-5/en/

  10. American Academy of Pediatrics. Métodos anticonceptivos eficaces para las adolescentes sexualmente activas. 2014. https://www.healthychildren.org/Spanish/ages-stages/ teen/dating-sex/Paginas/birth-control-for-sexually-activeteens. aspx

  11. von Hertzen H, et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicenter randomized trial. Lancet 2002;360:1803- 10. https://doi.org/10.1016/S0140-6736(02)11767-3

  12. Noe G et al. Contraceptive efficacy of emergency contraception with levonorgestrel given before or after ovulation. Contraception 2011;84:486-92. https://doi.org/10.1016/j. contraception.2011.03.006

  13. Ellertson C, et al. Modifying the Yuzpe regimen of emergency contraception: a multicenter randomized controlled trial. Obstet Gynecol 2003;101:1160-7.

  14. Piaggio G, et al. Effect on pregnancy rates of the delay in the administration of levonorgestrel for emergency contraception: a combined analysis of four WHO trials. Contraception 2011;84:35-9. https://doi.org/10.1016/j. contraception.2010.11.010

  15. Task Force on postovulatory methods of fertility regulation. Randomized controlled trial of levonorgestrel versus the Yuzpe of combined oral contraception for emergency contraception. Task Force on postovulatory methods of fertility regulation. Lancet 1998;352:428-33.

  16. Cleland K, et al. Emergency contraception review: evidence-based recommendations for clinicians. Clin Obstet Gynecol 2014;57:741-50. https://doi.org/10.1097/ GRF.0000000000000056.

  17. Rosato E, Farris M, Bastianelli C. Mechanism of action of ulipristal acetate for emergency contraception: a systematic review. Front Pharmacol 2016;6:315. https://doi. org/10.3389/fphar.2015.00315

  18. Glasier A, et al. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. Contraception 2011;84:363-7. https://doi.org/10.1016/j. contraception.2011.02.009.

  19. Neinstein L. Combined hormonal contraception. In: Neinstein L, et al, editors. Adolescent health care. a practical guide, 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2008.

  20. Trenor CC, et al. Hormonal contraception and thrombotic risk: a multidisciplinary approach. Pediatrics 2011;127:347- 57. https://doi.org/10.1542/peds.2010-2221.

  21. Committee on Adolescence. Contraception for adolescents. Pediatrics 2014;134(4):1244-56. http://pediatrics.aappublications. org/content/134/4/e1244

  22. Hatcher RA, et al. Contraceptive technology. 20th Ed. New York: Ardent Media; 2011.

  23. Vasey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004. Br J Cancer 2006;95:385-9. https://doi.org/10.1038/sj.bjc.6603260

  24. Raine TR, et al. One-year contraceptive continuation and pregnancy in adolescent girls and women initiating hormonal contraceptives. Obstet Gynecol 2011;117:363-71. https://doi.org/10.1097/AOG.0b013e31820563d3.

  25. Dore DD, et al. Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users. Contraception 2010;81:408-13. https://doi. org/10.1016/j.contraception.2009.12.009

  26. Rubinstein ML, et al. An evaluation of the use for of the transdermal contraceptive patch in adolescents. J Adolesc Health 2004;34:395-401. 10.1016/j.jadohealth. 2003.08.017

  27. Stewart FH, et al. Adolescent and young women`s experience with the vaginal ring and oral contraceptive pills. J Pediatr Adolesc Gynecol 2007;20:345-51. https://doi. org/10.1016/j.jpag.2007.06.001

  28. Guida M, et al. Effects of two types of hormonal contraception oral versus intravaginal on the sexual life of women and their partners. Hum Reprod 2005;20:1100-6. https:// doi.org/10.1093/humrep/deh686

  29. American Academy of Pediatrics. Métodos anticonceptivos eficaces para las adolescentes sexualmente activas. 2014. https://www.healthychildren.org/Spanish/ages-stages/ teen/dating-sex/Paginas/birth-control-for-sexually-activeteens. aspx.

  30. Belsey EM. The association between vaginal bleeding patterns and reasons for discontinuation of contraceptive use. Contraception 1988;38:207-25.

  31. Hubacher D, et al. Menstrual patterns changes for levonorgestrel subdermal implants and depo medroxyprogesterone: systematic review and evidence-based comparisons. Contraception 2009;80:113-8. https://doi.org/10.1016/j. contraception.2009.02.008

  32. Lara TE, et al. Bone mineral density in adolescent female using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol 2004;17:17-21. https://doi.org/10.1016/j. contraception.2009.02.008

  33. Harel Z, al. Recovery of bone mineral density in adolescent following the use of depot medroxyprogesterone acetate contraceptive injections. Contraception 2010;81:281-91. https://doi.org/10.1016/j.contraception.2009.11.003.

  34. Bonny A E, Secic M, Crower B. Early weight gain related to later weight gain in adolescents with depot medroxyprogesterone acetate. Obstet Gynecol 2011;117:793-7. https://doi.org/10.1097/AOG.0b013e31820f387c.

  35. Harel Z, et al. Adolescents´ reasons for and experience after discontinuation of the long-acting contraceptives Depo- Provera and Norplant. J Adolesc Health 1996;19:118-23. https://doi.org/10.1016/1054-139X(95)00322-J

  36. Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group, The American College of Obstetricians and Gynecologists. Committee Opinion No. 539. Adolescents and long-acting reversible contraception: implants and intrauterine devices. Obstet Gynecol 2012;120:983- 8. https://doi.org/10.1097/AOG.0b013e3182723b7d

  37. Rome E. Use of long-acting reversible contraceptives to reduce the rate of teen pregnancy. Cleveland Clin J Med 2015;82:S8-12. https://doi.org/10.3949/ccjm.82.s1.02.

  38. Francis JKR, Gold MA. Long-acting reversible contraception for adolescents. A review. JAMA Pediatr 2017;171(7):694- 701. https://doi.org/10.1001/jama pediatrics.2017.0598.

  39. Graesslin O, Korver T. The contraceptive efficacy of Implanon: a review of clinical trials and marketing experience. Eur J Contracept Reprod Health Care 2008;13(Suppl 1):4- 12. https://doi.org/10.1080/13625180801942754.

  40. Modesto W, et al. Body composition and bone mineral density in users of the etonogestrel-releasing contraceptive implant. Arch Gynecol Obstet 2015;292:1387-91. https:// doi.org/10.1007/s00404-015-3784-0.

  41. Darney P, et al. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results for 11 international clinical trials. Fertil Steril 2009;91:1646-53. https://doi. org/10.1016/j.fertnstert.2008.02.140.

  42. Berlan E, et al. Twelve-month discontinuation of etonogestrel implant in an outpatient pediatric setting. Contraception 2017;94:81-6. https://doi.org/10.1016/j. contraception.2016.02.030

  43. Kapp N, et al. Progesten-only contraceptive use among breast-feeding women: a systematic review. Contraception 2010;82:17-37. https://doi.org/10.1016/j.contraception. 2010.02.002.

  44. Committee on Adolescence. Contraception for adolescents. Pediatrics 2014;134(4):1244-56. http://pediatrics.aappublications. org/content/134/4/e1244

  45. Schmidt E O, et al. Adolescent experience with intrauterine devices: a qualitative study. J Adolesc Health 2015:57:381- 6. https://doi.org/10.1016/j.jadohealth.2015.05.001

  46. López LM, et al. Interventions for pain with intrauterine device insertion. Cochrane Database Syst Rev 2015;15:7: CD007373. https://doi.org/10.1002/14651858.CD007373. pub3.

  47. Trusell J. Update on and correction to the cost-effectiveness of contraceptives in the United States. Contraception 2012;85(6):611. https://doi.org/10.1016/j.contraception. 2012.02.009

  48. Hubacher D, et al. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N Engl J Med 2001;345: 561-7. https://doi.org/10.1056/ NEJMoa010438

  49. Hov GG, et al. Use of IUD and subsequent fertility: follow-up after participation in a randomized clinical trial. Contraception 2007;75:88-92. https://doi.org/10.1016/j. contraception.2006.09.010

  50. Deans EI, Grimes DA. Intrauterine devices for adolescents: a systematic review. Contraception 2009;79:418-23. https:// doi.org/10.1016/j.contraception.2008.12.009.

  51. Thonneau P, et al. Risk factors for IUD failure results of a large multicentre case-control study. Hum Reprod 2006;21:2612-6. https://doi.org/10.1093/humrep/del208

  52. Ogburn JA, et al. Barriers to intrauterine device insertion in postpartum women. Contraception 2005;72:426-9. https://doi.org/10.1016/j.contraception.2005.05.016

  53. Patseadon M, Michala L. Usage of the levonorgestrelreleasing intrauterine device system in adolescent: what is the evidence so far? Arch Gynecol Obstet 2017;295:529-41. https://doi.org/10.1007/s00404-016-4261-0.

  54. Spies EL, et al. Young women´s knowledge, attitudes, and behaviors related to long-acting reversible contraceptives. Womens Health Issues 2010;20:394-9. https://doi. org/10.1016/j.whi.2010.07.005.

  55. Mestad R, et al. Acceptance of long-acting reversible contraceptive methods by adolescent participants in the Contraceptive CHOICE Project. Contraception 2011;84:493- 8. https://doi.org/10.1016/j.contraception.2011.03.001.

  56. Espey E, Ogburn T. Long-acting reversible contraceptives: intrauterine devices and the contraceptive implant. Obstet Gynecol 2011:117:705-19. https://doi.org/10.1097/ AOG.0b013e31820ce2f0.

  57. Schmidt E O, et al. Adolescence experiences with IUD´s: a qualitative study. J Adolesc Health 2015;57:381-6. https:// doi.org/10.1016/j.jadohealth.2015.05.001

  58. Abraham M, et al. Young age, nulliparity, and contraception of long-acting reversible contraceptive methods. Obstet Gynecol 2015;126:823-9. https://doi.org/10.1097/ AOG.0000000000001036.

  59. Jatlaoui TC, et al. The safety of intrauterine devices among young women: a systematic review. Contraception 2017;95:17-39. https://doi.org/10.1016/j.contraception. 2016.10.006

  60. Seidman DS. Non-contraceptive benefits of hormonal contraception: time forrenewed awareness. Eur J Contracept Reprod Health Care 2011;16:407-8. https://doi.org/10.31 09/13625187.2011.630492.

  61. Potter J, Soren K. Long-acting reversible contraception and condon use: we need a better message. JAMA Pediatr 2016;170:417-8. https://doi.org/10.1001/jamapediatrics. 2016.0141.

  62. Espinera AR, et al. Counseling by epiletologist affects contraceptive choices of women with epilepsy. Epilepsy Behav 2016;65:1-6. https://doi.org/10.1016/j.yebeh.2016.08.021

  63. Samaritano LR. Contraception in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus 2014;23:1242-5. https://doi. org/10.1177/0961203314528062.

  64. Martin J, et al. Fertility and contraception in women with inflammatory bowel disease. Gastroenterol Hepatol (N Y) 2016;12:101-9.

  65. O´Brien SH, et al. Hormonal contraception and risk of thromboembolism in women with diabetes. Diabetes Care 2017;40:233-8. https://doi.org/10.2337/dci17-0004.

  66. Amies Oelschlager AM, et al. Long-acting reversible contraception in adolescents with cardiovascular conditions. J Pediatr Adolesc Gynecol 2014;27:353-5. https://doi. org/10.1016/j.jpag.2014.01.102.

  67. Krajewski CM, et al. Contraceptive options for women with history of solid-organ transplantation. Transplantation 2013;95:1183-6. https://doi.org/10.1097/ TP.0b013e31827c64de.

  68. Martin-Joliston MK, et al. Therapeutic amenorrhea in patients at risk for thrombocytopenia. Obstet Gynecol Surv 2008;63:395-402. https://doi.org/10.1097/ OGX.0b013e3181706620.

  69. Silva CD, et al. Levonorgestrel intrauterine systems as a treatment for severe menorrhagia in adolescent with type III von Willebrand disease. BMJ Care Rep 2013. https://doi. org/10.1136/bcr_2013-008833.

  70. Savosi I, et al. Complication rates associated with levonorgestrel intrauterine system use in adolescents with developmental dissabilities. J Pediatr Adolesc Gynecol 2014;27:25-8. https://doi.org/10.1016/j.jpag.2013.08.010.

  71. Amory JK. Male contraception. Fertil Steril 2016;106:1303- 9. doi: https://doi.org/10.1016/j.fertnstert.2016.08.036.

  72. Hardee K, et al. Are men well served by family planning programs? Reproductive Health 2017;14:14. https://doi. org/10.1186/s12978-017-0278-5.

  73. Neyro JL, et al. Mitos y realidades de los anticonceptivos reversibles de larga duración. Ginecol Obstet Mex 2015;83:707-721. https://ginecologiayobstetricia.org.mx/ secciones/articulos-de-revision/mitos-y-realidades-de-losanticonceptivos- reversibles-de-larga-duracion-2/

  74. Cristobal I, et al. The new LNG-releasing IUS: a new opportunity to reduce the burden of unintended pregnancy. Eur J Obstet Gynecol Reprod Biol 2015;190:58-64. https://doi. org/10.1016/j.ejogrb.2015.04.016.

  75. Neyro JL, et al. Anticoncepción y bioética: entre la objeción de conciencia y el principio de autonomía. Ginecol Obstet Mex 2015;83:125-138. https://ginecologiayobstetricia.org. mx/secciones/editorial/anticoncepcion-y-bioetica-entrela- objecion-de-conciencia-y-el-principio-de-autonomia/




2020     |     www.medigraphic.com